Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02601885 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02601885 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 20 participants.
The verdict
NCT02601885, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).
Interventions
- OTHER Placebo
- DRUG ABT-555
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-10-18 |
| Est. Completion | 2018-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02601885
The ClinicalTrials.gov registry entry for NCT02601885 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02601885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02601885 about?
NCT02601885 is a clinical study titled "A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis". This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).
What is the current status of trial NCT02601885?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-10-18. Estimated completion is 2018-04-20.
What interventions are being tested in trial NCT02601885?
The interventions under investigation include: Placebo (OTHER), ABT-555 (DRUG).
Who is sponsoring clinical trial NCT02601885?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.